PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board

Orforglipron: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for Orforglipron across studied indications.

Back to Orforglipron overview

Research Summary

Orforglipron has completed its Phase 3 ATTAIN program with 10+ RCTs and 5,000+ subjects. ATTAIN-1 (n=1,977) demonstrated 9.4% weight loss at 36 mg vs 2.4% placebo over 52 weeks. ATTAIN-2 (n=1,425) showed 1.4% HbA1c reduction for type 2 diabetes. Phase 2 trials established dose-response relationships and safety. While efficacy sits below injectable semaglutide (~15%) and tirzepatide (~20-22%), orforglipron's oral convenience represents a significant advancement for patients unable or unwilling to inject. FDA submission is expected Q4 2025-Q1 2026. Cardiovascular outcomes data are pending.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
Obesity / weight management Tier B 4 Phase 3 ATTAIN-1 showed 9.4% weight loss at 36 mg; not yet FDA-approved
Type 2 diabetes (glycemic control) Tier B 4 Phase 3 ATTAIN-2 showed 1.4% HbA1c reduction; not yet FDA-approved
Cardiovascular risk reduction Tier D 0 No CVOT data available; outcomes trial expected completion 2027-2028

Graded using our evidence tier methodology.

Research Gap Score /10

Higher score = larger gap between therapeutic potential and available clinical evidence.

Citations (2 sources)

  1. 1. Orforglipron Phase 2 trial in type 2 diabetes Clinical Trial

    Wharton S, Blevins T, Connery L, et al. (2023), New England Journal of Medicine

  2. 2. Orforglipron Phase 2 trial in obesity Clinical Trial

    Frias JP, Hsia DS, Engel SS, et al. (2023), New England Journal of Medicine